HA

Hanseatic Asset Management

Europe, England, United Kingdom, London

Description

Hanseatic Asset Management is a Comprehensive investment management and advisory service to global investors.

Investor Profile

Hanseatic Asset Management has made 3 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Private Equity (33%)
  • Series G (33%)
  • Series Unknown (33%)

Country Focus

  • Germany (67%)
  • United States (33%)

Industry Focus

  • Biotechnology
  • Medical
  • Therapeutics
  • Health Care
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Hanseatic Asset Management frequently co-invest with?

Co-Investments: 1
HP
Europe, Baden-Wurttemberg, Germany, Heidelberg
Co-Investments: 2
BR
North America, California, United States, San Francisco
Co-Investments: 1
Entrepreneurs Fund
Europe, England, United Kingdom, London
Co-Investments: 1
Co-Investments: 1
BG
Europe, England, United Kingdom, London
Co-Investments: 1
Future Capital Development Fund
North America, Virginia, United States, Richmond
Co-Investments: 1
Alta Partners
North America, Mississippi, United States, Jackson
Co-Investments: 1
FR
Europe, Luxembourg, Luxembourg, Luxembourg
Co-Investments: 1
Bayern Kapital
Europe, Bayern, Germany, Landshut
Co-Investments: 2

What are some of recent deals done by Hanseatic Asset Management?

Vasopharm

Würzburg, Bayern, Germany

Vasopharm is focused on the R&D of novel therapeutics for the treatment of cerebro and cardiovascular diseases and their symptoms.

BiotechnologyMedicalTherapeutics
Private EquityJul 11, 2019
Amount Raised: $10,687,306
Vasopharm

Würzburg, Bayern, Germany

Vasopharm is focused on the R&D of novel therapeutics for the treatment of cerebro and cardiovascular diseases and their symptoms.

BiotechnologyMedicalTherapeutics
Series GJan 21, 2016
Amount Raised: $21,737,500
The Medicines Company

Parsippany, New Jersey, United States

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective

BiotechnologyHealth CarePharmaceutical
Series UnknownJan 1, 1999